Ensysce Biosciences, Inc.
ENSC
$0.25
$0.00-1.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.75% | 1.51% | 415.60% | 256.36% | 133.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.75% | 1.51% | 415.60% | 256.36% | 133.58% |
| Cost of Revenue | 43.73% | 87.03% | 58.36% | 26.72% | -4.85% |
| Gross Profit | -164.27% | -394.96% | 57.42% | 56.42% | 62.49% |
| SG&A Expenses | 4.45% | -2.44% | -8.89% | -8.18% | -11.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.20% | 44.67% | 26.71% | 11.34% | -7.79% |
| Operating Income | -52.16% | -74.91% | 31.17% | 31.45% | 37.21% |
| Income Before Tax | -27.40% | -38.42% | 41.65% | 40.99% | 24.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.40% | -38.42% | 41.65% | 40.99% | 24.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 400.00% | -81.82% | -91.30% | -100.00% | -99.24% |
| Net Income | -27.40% | -38.43% | 41.64% | 40.95% | 24.74% |
| EBIT | -52.16% | -74.91% | 31.17% | 31.45% | 37.21% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 68.65% | 76.85% | 90.21% | 87.48% | 82.30% |
| Normalized Basic EPS | 68.65% | 76.84% | 90.20% | 87.47% | 82.73% |
| EPS Diluted | 68.65% | 76.85% | 90.21% | 87.48% | 82.30% |
| Normalized Diluted EPS | 68.65% | 76.84% | 90.20% | 87.47% | 82.73% |
| Average Basic Shares Outstanding | 256.44% | 320.98% | 298.02% | 310.92% | 350.24% |
| Average Diluted Shares Outstanding | 256.44% | 320.98% | 298.02% | 310.92% | 350.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |